Cargando…

Modeling of the Aqueous Solubility of N-butyl-N-methyl-1-phenylpyrrolo[1,2-a] pyrazine-3-carboxamide: From Micronization to Creation of Amorphous–Crystalline Composites with a Polymer

N-butyl-N-methyl-1-phenylpyrrole[1,2-a] pyrazine-3-carboxamide (GML-3) is a potential candidate for combination drug therapy due to its anxiolytic and antidepressant activity. The anxiolytic activity of GML-3 is comparable to diazepam. The antidepressant activity of GML-3 is comparable to amitriptyl...

Descripción completa

Detalles Bibliográficos
Autores principales: Markeev, Vladimir B., Tishkov, Sergey V., Vorobei, Anton M., Parenago, Olga O., Blynskaya, Evgenia V., Alekseev, Konstantin V., Marakhova, Anna I., Vetcher, Alexandre A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611044/
https://www.ncbi.nlm.nih.gov/pubmed/37896380
http://dx.doi.org/10.3390/polym15204136
_version_ 1785128398968848384
author Markeev, Vladimir B.
Tishkov, Sergey V.
Vorobei, Anton M.
Parenago, Olga O.
Blynskaya, Evgenia V.
Alekseev, Konstantin V.
Marakhova, Anna I.
Vetcher, Alexandre A.
author_facet Markeev, Vladimir B.
Tishkov, Sergey V.
Vorobei, Anton M.
Parenago, Olga O.
Blynskaya, Evgenia V.
Alekseev, Konstantin V.
Marakhova, Anna I.
Vetcher, Alexandre A.
author_sort Markeev, Vladimir B.
collection PubMed
description N-butyl-N-methyl-1-phenylpyrrole[1,2-a] pyrazine-3-carboxamide (GML-3) is a potential candidate for combination drug therapy due to its anxiolytic and antidepressant activity. The anxiolytic activity of GML-3 is comparable to diazepam. The antidepressant activity of GML-3 is comparable to amitriptyline. GML-3 is an 18 kDa mitochondrial translocator protein (TSPO) ligand and is devoid of most of the side effects of diazepam, which makes the research on the creation of drugs based on it promising. However, its low water solubility and tendency to agglomerate prevented its release. This research aimed to study the effect of dry grinding, the rapid expansion of a supercritical solution (RESS), and the eutectic mixture (composite) of GML-3 with polyvinylpyrrolidone (PVP) on the particle size, dissolution rate, and lattice retention of GML-3. The use of supercritical CO(2) in the RESS method was promising in terms of particle size reduction, resulting in a reduction in the particle size of GML-3 to 20–40 nm with a 430-fold increase in dissolution rate. However, in addition to particle size reduction after RESS, GML-3 began to show signs of a polymorphism phenomenon, which was also studied in this article. It was found that coarse grinding reduced particle size by a factor of 2 but did not significantly affect solubility or crystal structure. Co-milling with the polymer made it possible to level the effect of the appearance of a residual electrostatic charge on the particles, as in the case of grinding, and the increased solubility in the resulting mechanical mixtures of GML-3 with the polymer may also indicate the dissolving properties of polymers (an increase in 400–800 times). The best result in terms of GML-3 solubility was demonstrated by the resulting GML-3:PVP composite at a ratio of 1:4, which made it possible to achieve a solubility of about 80% active pharmaceutical ingredient (API) within an hour with an increase in the dissolution rate by 1600 times. Thus, the creation of composites is the most effective method for improving the solubility of GML-3, superior to micronization.
format Online
Article
Text
id pubmed-10611044
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106110442023-10-28 Modeling of the Aqueous Solubility of N-butyl-N-methyl-1-phenylpyrrolo[1,2-a] pyrazine-3-carboxamide: From Micronization to Creation of Amorphous–Crystalline Composites with a Polymer Markeev, Vladimir B. Tishkov, Sergey V. Vorobei, Anton M. Parenago, Olga O. Blynskaya, Evgenia V. Alekseev, Konstantin V. Marakhova, Anna I. Vetcher, Alexandre A. Polymers (Basel) Article N-butyl-N-methyl-1-phenylpyrrole[1,2-a] pyrazine-3-carboxamide (GML-3) is a potential candidate for combination drug therapy due to its anxiolytic and antidepressant activity. The anxiolytic activity of GML-3 is comparable to diazepam. The antidepressant activity of GML-3 is comparable to amitriptyline. GML-3 is an 18 kDa mitochondrial translocator protein (TSPO) ligand and is devoid of most of the side effects of diazepam, which makes the research on the creation of drugs based on it promising. However, its low water solubility and tendency to agglomerate prevented its release. This research aimed to study the effect of dry grinding, the rapid expansion of a supercritical solution (RESS), and the eutectic mixture (composite) of GML-3 with polyvinylpyrrolidone (PVP) on the particle size, dissolution rate, and lattice retention of GML-3. The use of supercritical CO(2) in the RESS method was promising in terms of particle size reduction, resulting in a reduction in the particle size of GML-3 to 20–40 nm with a 430-fold increase in dissolution rate. However, in addition to particle size reduction after RESS, GML-3 began to show signs of a polymorphism phenomenon, which was also studied in this article. It was found that coarse grinding reduced particle size by a factor of 2 but did not significantly affect solubility or crystal structure. Co-milling with the polymer made it possible to level the effect of the appearance of a residual electrostatic charge on the particles, as in the case of grinding, and the increased solubility in the resulting mechanical mixtures of GML-3 with the polymer may also indicate the dissolving properties of polymers (an increase in 400–800 times). The best result in terms of GML-3 solubility was demonstrated by the resulting GML-3:PVP composite at a ratio of 1:4, which made it possible to achieve a solubility of about 80% active pharmaceutical ingredient (API) within an hour with an increase in the dissolution rate by 1600 times. Thus, the creation of composites is the most effective method for improving the solubility of GML-3, superior to micronization. MDPI 2023-10-18 /pmc/articles/PMC10611044/ /pubmed/37896380 http://dx.doi.org/10.3390/polym15204136 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Markeev, Vladimir B.
Tishkov, Sergey V.
Vorobei, Anton M.
Parenago, Olga O.
Blynskaya, Evgenia V.
Alekseev, Konstantin V.
Marakhova, Anna I.
Vetcher, Alexandre A.
Modeling of the Aqueous Solubility of N-butyl-N-methyl-1-phenylpyrrolo[1,2-a] pyrazine-3-carboxamide: From Micronization to Creation of Amorphous–Crystalline Composites with a Polymer
title Modeling of the Aqueous Solubility of N-butyl-N-methyl-1-phenylpyrrolo[1,2-a] pyrazine-3-carboxamide: From Micronization to Creation of Amorphous–Crystalline Composites with a Polymer
title_full Modeling of the Aqueous Solubility of N-butyl-N-methyl-1-phenylpyrrolo[1,2-a] pyrazine-3-carboxamide: From Micronization to Creation of Amorphous–Crystalline Composites with a Polymer
title_fullStr Modeling of the Aqueous Solubility of N-butyl-N-methyl-1-phenylpyrrolo[1,2-a] pyrazine-3-carboxamide: From Micronization to Creation of Amorphous–Crystalline Composites with a Polymer
title_full_unstemmed Modeling of the Aqueous Solubility of N-butyl-N-methyl-1-phenylpyrrolo[1,2-a] pyrazine-3-carboxamide: From Micronization to Creation of Amorphous–Crystalline Composites with a Polymer
title_short Modeling of the Aqueous Solubility of N-butyl-N-methyl-1-phenylpyrrolo[1,2-a] pyrazine-3-carboxamide: From Micronization to Creation of Amorphous–Crystalline Composites with a Polymer
title_sort modeling of the aqueous solubility of n-butyl-n-methyl-1-phenylpyrrolo[1,2-a] pyrazine-3-carboxamide: from micronization to creation of amorphous–crystalline composites with a polymer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611044/
https://www.ncbi.nlm.nih.gov/pubmed/37896380
http://dx.doi.org/10.3390/polym15204136
work_keys_str_mv AT markeevvladimirb modelingoftheaqueoussolubilityofnbutylnmethyl1phenylpyrrolo12apyrazine3carboxamidefrommicronizationtocreationofamorphouscrystallinecompositeswithapolymer
AT tishkovsergeyv modelingoftheaqueoussolubilityofnbutylnmethyl1phenylpyrrolo12apyrazine3carboxamidefrommicronizationtocreationofamorphouscrystallinecompositeswithapolymer
AT vorobeiantonm modelingoftheaqueoussolubilityofnbutylnmethyl1phenylpyrrolo12apyrazine3carboxamidefrommicronizationtocreationofamorphouscrystallinecompositeswithapolymer
AT parenagoolgao modelingoftheaqueoussolubilityofnbutylnmethyl1phenylpyrrolo12apyrazine3carboxamidefrommicronizationtocreationofamorphouscrystallinecompositeswithapolymer
AT blynskayaevgeniav modelingoftheaqueoussolubilityofnbutylnmethyl1phenylpyrrolo12apyrazine3carboxamidefrommicronizationtocreationofamorphouscrystallinecompositeswithapolymer
AT alekseevkonstantinv modelingoftheaqueoussolubilityofnbutylnmethyl1phenylpyrrolo12apyrazine3carboxamidefrommicronizationtocreationofamorphouscrystallinecompositeswithapolymer
AT marakhovaannai modelingoftheaqueoussolubilityofnbutylnmethyl1phenylpyrrolo12apyrazine3carboxamidefrommicronizationtocreationofamorphouscrystallinecompositeswithapolymer
AT vetcheralexandrea modelingoftheaqueoussolubilityofnbutylnmethyl1phenylpyrrolo12apyrazine3carboxamidefrommicronizationtocreationofamorphouscrystallinecompositeswithapolymer